Eugene Swenson is a Gastroenterology physician affiliated with Alexion Pharmaceuticals. OpenAlex indexes 39 publications with 1,849 citations (h-index 14); ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 Cedar St
Lmp1080
New Haven, CT 065208019
Telephone
203-785-4138Registry record last updated 6 Nov 2009.
Clinical trials
- Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
Sponsor: Alexion Pharmaceuticals, Inc.
- Bioavailability Study of 2 Oral Formulations of ALXN1840
Sponsor: Alexion Pharmaceuticals, Inc.
- Copper Balance in Healthy Participants Administered ALXN1840
Sponsor: Alexion Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
2 NIH research awards on record, funded 2006–2011 per NIH RePORTER. The latest:
- Investigation of the liver progenitor cell niche using CK19 lineage tracing
Yale University
FY2011$81,964R03DK088166 - Investigation of the liver progenitor cell niche using CK19 lineage tracing
Yale University
FY2010$82,750R03DK088166
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Journal of Clinical Oncology
2026 - Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
Journal of Clinical Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Anna Petryk
Alexion Pharmaceuticals
Laura Gault, MD
Alexion Pharmaceuticals
Dallas Dunn
Alexion Pharmaceuticals
Toby Bates, DO
Alexion Pharmaceuticals
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”